<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04759768</url>
  </required_header>
  <id_info>
    <org_study_id>OPNT003-PK-001</org_study_id>
    <nct_id>NCT04759768</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Evaluation of Intranasal Nalmefene</brief_title>
  <official_title>Two-Period, Two-Treatment, Randomized Crossover Study of the Pharmacokinetics of Nalmefene by Intranasal and Intramuscular Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Opiant Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Opiant Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the pharmacokinetics (how the body absorbs, breaks down and&#xD;
      eliminates drug from your body) of nalmefene when given intranasally (IN;into the nose)&#xD;
      compared to a dose of nalmefene when given intramuscularly (IM; into the muscle); to compare&#xD;
      the blood levels of nalmefene when given IN to nalmefene when given IM; and to evaluate the&#xD;
      safety and tolerability of nalmefene IN.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, randomized, 2-period, 2-treatment, 2-sequence, crossover study in 68 healthy&#xD;
      volunteers. Subjects will be assigned to each of the 2 possible sequences. Each subject will&#xD;
      receive 2 treatments during the 2 dosing periods: Intranasal (IN) dose of 3 mg nalmefene&#xD;
      hydrochloride and intramuscular (IM) dose of 1.0 mg nalmefene, with a 4 day washout period&#xD;
      between doses. Screening can occur up to 28 days before baseline admission, subjects will&#xD;
      then stay in the inpatient facility for 7 days to complete the treatment phase of the study&#xD;
      and will be discharged following completion of the discharge procedures at the end of the&#xD;
      last period. Subjects will be called 3 to 5 days after discharge to inquire concerning&#xD;
      Adverse Events (AEs) and concomitant medications since discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2021</start_date>
  <completion_date type="Actual">May 24, 2021</completion_date>
  <primary_completion_date type="Actual">May 17, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>48 hours</time_frame>
    <description>Maximum concentration of plasma nalmefene comparing IN to IM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>48 hours</time_frame>
    <description>Time to maximum concentration of plasma nalmefene comparing IN to IM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>48 hours</time_frame>
    <description>Area under the curve of plasma nalmefene comparing IN to IM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t1/2)</measure>
    <time_frame>48 hours</time_frame>
    <description>Half life of plasma nalmefene comparing IN to IM</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Intranasal Nalmefene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nalmefene hydrochloride nasal spray, 3mg, 1 spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular Nalmefene</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nalmefene injection, 1mg, 1 injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalmefene Hydrochloride</intervention_name>
    <description>3mg nasal spray</description>
    <arm_group_label>Intranasal Nalmefene</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalmefene</intervention_name>
    <description>1mg intramuscular injection</description>
    <arm_group_label>Intramuscular Nalmefene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 18 to 55 years inclusive&#xD;
&#xD;
          -  BMI ranging from 18 to 30 kg/m2, inclusive&#xD;
&#xD;
          -  Adequate venous access&#xD;
&#xD;
          -  Subjects must be non-smokers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant disease&#xD;
&#xD;
          -  Significant trauma injury, major surgery, open biopsy within 30 days prior to&#xD;
             screening&#xD;
&#xD;
          -  Following an abnormal diet 4 weeks prior to screening&#xD;
&#xD;
          -  Use of over the counter medications, dietary supplements, herbal products, vitamins or&#xD;
             opioid analgesics 14 days before intervention&#xD;
&#xD;
          -  Use of enzyme altering drugs 30 days before intervention&#xD;
&#xD;
          -  Use of nasal products 28 days before intervention and throughout the study&#xD;
&#xD;
          -  Previous or current opioid, alcohol, or other drug dependence&#xD;
&#xD;
          -  Donated or received blood 30 days before intervention&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding at screening&#xD;
&#xD;
          -  Women of childbearing potential unless surgically sterile or use effective&#xD;
             contraception&#xD;
&#xD;
          -  Current or recent upper respiratory tract infection&#xD;
&#xD;
          -  Allergic to nalmefene&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Bass, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Worldwide Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Nalmefene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

